Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials

Nkarta, Inc.

• Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.
• Net loss $27.8M ($0.37 per basic/diluted share) for Q1 2026; R&D expense $25.0M, G&A $5.9M.
• FDA agreed to protocol amendments allowing outpatient dosing in community settings, re-dosing, and adding RA to Ntrust-2.
• Enrollment ongoing at 4 billion cells per dose (12B total) across Ntrust-1 and Ntrust-2 for multiple autoimmune indications.
• Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.